Marchex - MCHX Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marchex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Marchex stock.
View analyst ratings for Marchex or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month target prices for Marchex's stock. Their MCHX stock forecasts range from $4.00 to $4.00. On average, they anticipate Marchex's stock price to reach $4.00 in the next year. This suggests a possible upside of 96.1% from the stock's current price.
View analysts' price targets for Marchex or view top-rated stocks among Wall Street analysts.

Marchex's stock was trading at $2.48 at the beginning of 2022. Since then, MCHX shares have decreased by 17.7% and is now trading at $2.04.
View the best growth stocks for 2022 here.

Marchex is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Marchex.

Marchex will be holding an earnings conference call on Tuesday, August 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

Marchex, Inc. (NASDAQ:MCHX) announced its quarterly earnings data on Thursday, May, 12th. The technology company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. The technology company earned $13.17 million during the quarter, compared to analysts' expectations of $13.04 million. Marchex had a negative net margin of 1.19% and a negative trailing twelve-month return on equity of 8.11%. During the same quarter last year, the business earned ($0.10) EPS.

8 employees have rated Marchex CEO Russell Horowitz, Michael Arends, and Ethan Caldwell. on Glassdoor.com. Russell Horowitz, Michael Arends, and Ethan Caldwell. has an approval rating of 58% among Marchex's employees. This puts Russell Horowitz, Michael Arends, and Ethan Caldwell. in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Marchex investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Enphase Energy (ENPH), NVIDIA (NVDA), OPKO Health (OPK), Nokia Oyj (NOK), Overstock.com (OSTK), Block (SQ) and Zynga (ZNGA).

Marchex trades on the NASDAQ under the ticker symbol "MCHX."

Shares of MCHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MCHX stock can currently be purchased for approximately $2.04.

Marchex (NASDAQ:MCHX) has a market capitalization of $86.31 million and generates $53.48 million in revenue each year. The technology company earns $-4,390,000.00 in net income (profit) each year or ($0.02) on an earnings per share basis.

Marchex employs 187 workers across the globe.

Marchex was founded in 2003.

Marchex's mailing address is 520 PIKE STREET SUITE 2000, SEATTLE WA, 98101. The official website for Marchex is www.marchex.com. The technology company can be reached via phone at (206) 331-3300, via email at ir@marchex.com, or via fax at 206-331-3695.